CD86 and synovial sarcoma: To study if an activated B cell phenotype, in terms of increased BTK and/or CD86 expression, was already present in recently diagnosed pSS patients, we analyzed peripheral blood mononuclear cells (PBMCs) from 27 pSS patients and compared these with 30 non-SS sicca patients (patient group 1; Table 1).